MASLD/MASH and Weight Loss

Article Type
Article
Changed
Tue, 09/26/2023 - 12:23
Display Headline
MASLD/MASH and Weight Loss
Author(s)
Arpan Mohanty, MD, MSc

Click to view more from Gastroenterology Data Trends 2023. 

References
  1. Younossi ZM et al. Gastroenterology. 2021;160(3):912-918. doi:10.1053/j.astro.2020.11.051
  2. Cusi K et al. Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
  3. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
  4. World obesity atlas 2023. World Obesity Day. Published March 2023. Accessed July 23, 2023. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
  5. Le MH et al. Clin Mol Hepatol. 2022;28(4):841-850. doi:10.3350/cmh.2022.0239
  6. Vilar-Gomez E et al. Gastroenterology. 2015;149(2):367-78.e5. doi:10.1053/j.gastro.2015.04.005
  7. Koutoukidis DA et al. Metabolism. 2021;115:154455. doi:10.1016/j.metabol.2020.154455
  8. Ma J et al. Gastroenterology. 2018;155(1):107-117. doi:10.1053/j.gastro.2018.03.038
  9. Ahern AL et al. Lancet. 2017;389(10085):2214-2225. doi:10.1016/S0140-6736(17)30647-5
  10. Newsome PN et al; NN9931-4296 Investigators. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395
  11. Armstrong MJ et al. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
  12. Gastaldelli A et al. Lancet Diabetes Endocrinol. 2022;10(6):393-406. doi:10.1016/S2213-8587(22)00070-5
  13. Kahl S et al. Diabetes Care. 2020;43(2):298-305. doi:10.2337/dc19-0641
Author and Disclosure Information

Assistant Professor of Medicine
Boston Medical Center
Boston University Chobanian & Avedisian School of Medicine
Boston, MA

Publications
GI and Hepatology News
Topics
Liver Disease
Author(s)
Arpan Mohanty, MD, MSc
Author(s)
Arpan Mohanty, MD, MSc
Author and Disclosure Information

Assistant Professor of Medicine
Boston Medical Center
Boston University Chobanian & Avedisian School of Medicine
Boston, MA

Author and Disclosure Information

Assistant Professor of Medicine
Boston Medical Center
Boston University Chobanian & Avedisian School of Medicine
Boston, MA

Click to view more from Gastroenterology Data Trends 2023. 

Click to view more from Gastroenterology Data Trends 2023. 

References
  1. Younossi ZM et al. Gastroenterology. 2021;160(3):912-918. doi:10.1053/j.astro.2020.11.051
  2. Cusi K et al. Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
  3. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
  4. World obesity atlas 2023. World Obesity Day. Published March 2023. Accessed July 23, 2023. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
  5. Le MH et al. Clin Mol Hepatol. 2022;28(4):841-850. doi:10.3350/cmh.2022.0239
  6. Vilar-Gomez E et al. Gastroenterology. 2015;149(2):367-78.e5. doi:10.1053/j.gastro.2015.04.005
  7. Koutoukidis DA et al. Metabolism. 2021;115:154455. doi:10.1016/j.metabol.2020.154455
  8. Ma J et al. Gastroenterology. 2018;155(1):107-117. doi:10.1053/j.gastro.2018.03.038
  9. Ahern AL et al. Lancet. 2017;389(10085):2214-2225. doi:10.1016/S0140-6736(17)30647-5
  10. Newsome PN et al; NN9931-4296 Investigators. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395
  11. Armstrong MJ et al. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
  12. Gastaldelli A et al. Lancet Diabetes Endocrinol. 2022;10(6):393-406. doi:10.1016/S2213-8587(22)00070-5
  13. Kahl S et al. Diabetes Care. 2020;43(2):298-305. doi:10.2337/dc19-0641
References
  1. Younossi ZM et al. Gastroenterology. 2021;160(3):912-918. doi:10.1053/j.astro.2020.11.051
  2. Cusi K et al. Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
  3. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
  4. World obesity atlas 2023. World Obesity Day. Published March 2023. Accessed July 23, 2023. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2023_Report.pdf
  5. Le MH et al. Clin Mol Hepatol. 2022;28(4):841-850. doi:10.3350/cmh.2022.0239
  6. Vilar-Gomez E et al. Gastroenterology. 2015;149(2):367-78.e5. doi:10.1053/j.gastro.2015.04.005
  7. Koutoukidis DA et al. Metabolism. 2021;115:154455. doi:10.1016/j.metabol.2020.154455
  8. Ma J et al. Gastroenterology. 2018;155(1):107-117. doi:10.1053/j.gastro.2018.03.038
  9. Ahern AL et al. Lancet. 2017;389(10085):2214-2225. doi:10.1016/S0140-6736(17)30647-5
  10. Newsome PN et al; NN9931-4296 Investigators. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395
  11. Armstrong MJ et al. Lancet. 2016;387(10019):679-690. doi:10.1016/S0140-6736(15)00803-X
  12. Gastaldelli A et al. Lancet Diabetes Endocrinol. 2022;10(6):393-406. doi:10.1016/S2213-8587(22)00070-5
  13. Kahl S et al. Diabetes Care. 2020;43(2):298-305. doi:10.2337/dc19-0641
Publications
GI and Hepatology News
Publications
GI and Hepatology News
Topics
Liver Disease
Article Type
Article
Display Headline
MASLD/MASH and Weight Loss
Display Headline
MASLD/MASH and Weight Loss
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Slideshow
Gate On Date
Fri, 09/22/2023 - 14:30
Un-Gate On Date
Fri, 09/22/2023 - 14:30
Use ProPublica
CFC Schedule Remove Status
Fri, 09/22/2023 - 14:30
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Slideshow Below. 

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), affects about 20% to 30% of the world population. About 1 in 4 of these patients have metabolic dysfunction–associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis)—which is associated with significant morbidity and mortality.

Although they affect the liver, these conditions are associated with extrahepatic diseases such as obesity, type 2 diabetes mellitus, and cardiovascular disease, which contribute to poor outcomes. Evidence has shown that weight loss is a key intervention for reduction of steatosis, MASH, and fibrosis in both lean and obese patients with MASLD. Modifications recommended for weight loss include potential pharmacological, surgical, or endoscopic approaches (in cases of severe obesity) that can prevent progression of MASLD as well as improve diabetes and reduce cardiovascular events.1-3

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Subscribe to Arpan Mohanty, MD, MSc